Sponsors (4)
Introduced March 12, 2025 by Thomas Roland Tillis · Last progress March 12, 2025
The bill aims to secure and speed access to medical goods—reducing shortages and boosting innovation—by reshaping trade, procurement, and oversight, but it risks higher costs, concentrated geopolitical and executive power, privacy concerns, and increased policy uncertainty for businesses and taxpayers.
Hospitals and patients will face fewer shortages of critical medical supplies and medicines because the Act pushes for diversified, more reliable supply chains and increased domestic/trusted‑partner capacity.
During emergencies, hospitals and patients can get faster access to needed medical goods because the Act expedites cross‑border movement and promotes regulatory harmonization to speed approvals and inspections.
Taxpayers and the nation may gain stronger national security protection by reducing dependence on a small set of foreign suppliers and encouraging reshoring or trusted‑partner manufacturing.
Taxpayers and consumers could face higher costs because reshoring, diversification, and incentives for domestic manufacturing may require subsidies, incentives, or higher prices.
The law concentrates significant authority in the Executive (to modify tariffs, grant/withdraw exemptions, and act quickly in emergencies), which could reduce congressional control over trade and emergency economic decisions.
Relying on a narrower set of 'trusted' partners risks creating new geopolitical dependencies that could leave the U.S. vulnerable if partner countries change policy or are subject to disruptions.
Based on analysis of 7 sections of legislative text.
Allows the President to make "trusted trade partner" agreements to lower or remove import duties and align rules for medical goods, with required congressional notice, review, and enforcement.
Authorizes the President to negotiate and implement "trusted trade partner" agreements that lower or eliminate import duties and align trade, regulatory, procurement, and IP rules for medical devices, pharmaceuticals, and related inputs to strengthen U.S. medical supply chain resilience. The measure requires advance notice to Congress, regular reporting, interagency consultations, review by advisory bodies and the ITC, and a congressional review period before duty changes take effect; it also sets monitoring and rapid remedial steps if a partner fails to meet commitments.